Skip to content

LL-37

Research Use Only
peptideInjection

Your body's natural antibiotic peptide. Fights bacteria, viruses, and fungi, breaks up biofilms, and supports wound healing while modulating immune response.

Key Facts

  • Classification
    LL-37 is the only human cathelicidin-derived antimicrobial peptide.
  • Primary Benefits
    Immune Support (8/10) · Inflammation (7/10) · Injury Healing (5/10)
  • Administration
    Injection
  • Typical Dose
    50-100 mcg subq daily, injected near the infection site. Cycle for 2-4 weeks.
  • Evidence Strength
    Moderate — 20 peer-reviewed studies referenced · Community sentiment 9/10
  • Stacks Well With
    Thymosin Alpha-1, BPC-157, KPV
  • Legal Status
    Research Use Only · not prescribable in US

Quick Facts

From price
$60
Type
peptide
Administration
Injection
Evidence
moderate
Studies referenced
20
Community sentiment
9/10
Stacks with
3 peptides
Regulatory
Research Use Only

Top benefits

🛡️ Immune Support
8/10
🧊 Inflammation
7/10
🩹 Injury Healing
5/10
1

Week 1–2

Enhanced innate antimicrobial defense. May notice faster resolution of minor infections. Improved wound healing speed.

2

Week 3–6

Biofilm disruption effects becoming apparent for chronic infections (Lyme, SIBO). Improved immune surveillance. Reduced chronic infection symptoms.

3

Week 8+

Sustained antimicrobial and immunomodulatory benefits. Chronic biofilm-associated infections may show significant improvement. Enhanced wound healing.

Common Side Effects

Injection site pain and rednessMild feverHerxheimer-like reactions (die-off symptoms)Fatigue
Tolerance: Not well-characterized — innate immune peptide
Cycling: 4-6 weeks on, 2-4 weeks off. Longer cycles for chronic biofilm infections under medical supervision.

Scientific Overview

LL-37 is the only human cathelicidin-derived antimicrobial peptide. This 37-residue amphipathic α-helical peptide exhibits broad-spectrum antimicrobial activity through membrane disruption. Also promotes chemotaxis, angiogenesis, TLR modulation, wound healing, and biofilm disruption.

Dosing

50-100 mcg subq daily, injected near the infection site. Cycle for 2-4 weeks.

Reconstitution, storage, injection sites & timing

Benefit Profile

🛡️ Immune Support
8/10
🧊 Inflammation
7/10
🩹 Injury Healing
5/10
🫃 Gut Health
4/10
Medical oversight strongly recommendedNot safe during pregnancy· 3 contraindications